Aptevo Therapeutics Inc.
NASDAQ: APVO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeffrey G. Lamothe
- Employees
- 37
- Headquarters
- Seattle, United States
- IPO year
- 2016
- Market cap
- $10.4M
- Website
- https://www.aptevotherapeutics.com
Loading APVO…
Loading profile data…Frequently asked questions about APVO
What does Aptevo Therapeutics Inc. (APVO) do?
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company primarily focused on pioneering immunotherapeutic agents for a variety of cancer treatments across the United States. Its foremost investigational drug, APVO436, is a bispecific antibody crafted to engage T-cells, which is currently undergoing a Phase 1b clinical study for acute...
Where does APVO trade?
Aptevo Therapeutics Inc. (APVO) trades on the NASDAQ Capital Market.
What sector is APVO in?
Aptevo Therapeutics Inc. (APVO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Aptevo Therapeutics Inc.?
Jeffrey G. Lamothe is the chief executive officer of Aptevo Therapeutics Inc. (APVO).
Where is Aptevo Therapeutics Inc. headquartered?
Aptevo Therapeutics Inc. is headquartered in United States.
Does APVO pay a dividend?
Aptevo Therapeutics Inc. (APVO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did APVO go public?
Aptevo Therapeutics Inc. (APVO) completed its initial public offering in 2016.